Immunome Inc (IMNM) - Total Assets
Based on the latest financial reports, Immunome Inc (IMNM) holds total assets worth $683.19 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Immunome Inc (IMNM) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Immunome Inc - Total Assets Trend (2018–2025)
This chart illustrates how Immunome Inc's total assets have evolved over time, based on quarterly financial data. Check tangible equity quality of Immunome Inc to evaluate the tangible quality of the company's equity base.
Immunome Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Immunome Inc's total assets of $683.19 Million consist of 96.7% current assets and 3.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 95.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Immunome Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IMNM market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Immunome Inc's current assets represent 96.7% of total assets in 2025, an increase from 47.5% in 2018.
- Cash Position: Cash and equivalents constituted 95.7% of total assets in 2025, up from 36.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Immunome Inc Competitors by Total Assets
Key competitors of Immunome Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €8.68 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
USA | $452.70 Million |
|
Tourmaline Bio Inc.
NASDAQ:TRML
|
USA | $269.30 Million |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230
|
China | CN¥1.32 Billion |
Immunome Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.69 | 4.08 | 8.99 |
| Quick Ratio | 14.69 | 4.08 | 9.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $615.79 Million | $167.03 Million | $36.54 Million |
Immunome Inc - Advanced Valuation Insights
This section examines the relationship between Immunome Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.01 |
| Latest Market Cap to Assets Ratio | 2.97 |
| Asset Growth Rate (YoY) | 184.4% |
| Total Assets | $683.19 Million |
| Market Capitalization | $2.03 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Immunome Inc's assets at a significant premium (2.97x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Immunome Inc's assets grew by 184.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Immunome Inc (2018–2025)
The table below shows the annual total assets of Immunome Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $683.19 Million | +184.38% |
| 2024-12-31 | $240.24 Million | +61.73% |
| 2023-12-31 | $148.54 Million | +517.73% |
| 2022-12-31 | $24.05 Million | -58.49% |
| 2021-12-31 | $57.92 Million | +30.10% |
| 2020-12-31 | $44.52 Million | +779.94% |
| 2019-12-31 | $5.06 Million | +13.76% |
| 2018-12-31 | $4.45 Million | -- |
About Immunome Inc
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine… Read more